PharmAust Limited (ASX:PAA) is a public company listed on the Australian Securities Exchange. The principal activities of the company are to develop its own drug discovery intellectual property, namely three platforms for the treatment of different types of cancers in humans and animals, as well as providing highly specialised medicinal and synthetic chemistry services on a contract basis to clients.
Pitney Pharmaceuticals Pty Ltd is an Australian company, which is in the business of developing therapeutic cancer products. It has exclusive rights to three oncology technology platforms, which are being developed with an aim to improve the outcomes of patients with inoperable and often terminal cancers. Pitney is a 100% wholly owned subsidiary of PharmAust Limited.
Epichem is a wholly owned subsidiary of the ASX listed company (PAA). Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in 35 countries worldwide for over 12 years. Epichem has a newly constructed state-of-the-art laboratory and has world class equipment and expertise in synthetic and medicinal chemistry for the cost effective synthesis of drug analogue libraries and intermediates.
PharmAust CEO Dr Richard Hopkins will be presenting at the Emerging Companies Expo in Sydney on the 8th of September.
Pharmaust © 2013 | All Rights Reserved Online Marketing & Website Design By Total Click Solutions
©2013 PharmAust Limited (ABN 35 094 006 023)
Tel: +61 8 6364 0899 | Fax: +61 8 9467 6111